Hims & Hers Health is trading 3.74% down at €24.20 after an FDA warning highlighted more than 1,700 adverse events involving compounded semaglutide and tirzepatide.
- The alert cited dosing errors, contamination, refrigeration problems and questionable ingredients, renewing concerns around compounded weight-loss treatments.
- The company-specific decline came despite broader U.S. equities and healthcare stocks trading higher, overshadowing its Australia expansion.
- Visa monitoring tied to elevated weight-loss subscription disputes adds another overhang.